Company news

Context Therapeutics Inc. news in 2026

Context Therapeutics Inc.'s news releases, calls and decks from 2026, newest first.

View company

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

September 9, 2026

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

August 5, 2026

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

July 6, 2026

Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76

June 15, 2026

Context Therapeutics to Present at the Jefferies Global Healthcare Conference

May 27, 2026

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

May 18, 2026

Context Therapeutics Reports First Quarter 2026 Operating and Financial Results

May 6, 2026

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

April 1, 2026

Context Therapeutics Reports Full Year 2025 Operating and Financial Results

March 22, 2026

Context Therapeutics to Participate in Upcoming Investor Conferences

February 9, 2026

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026

Decks in 2026